System for treating kidney disease in diabetic and non-diabetic patients

• US 20030176323A1
• Filed: 03/19/2003
• Published: 09/18/2003
• Est. Priority Date: 06/16/2000
• Status: Active Grant

• Current Assignee: Thomas T. Aoki
• Original Assignee: Thomas T. Aoki
• Inventors: Aoki, Thomas T.
• Granted Patent: US 6,821,527 B2
• Time in Patent Office: Days
• US Class Current: 514/3
• CPC Class Codes: A61K 38/28 Insulins

Abstract

The present invention is a system capable of improving the entire metabolic process and through its multiplicity of effects on neurovascular reactivity, intraglomerular pressure and hemodynamics, arresting the progression of overt diabetic nephropathy, improving intraglomerular hemodynamics, and thus arresting the progression of diabetic nephropathy and therefore reducing the risk of development of End Stage Renal Disease. The current system is for the treatment of kidney disease using insulin pulses to a patient utilizing Chronic Intermittent Intravenous Insulin Therapy to achieve the slowing, stopping or reversing of kidney disease in both diabetic and non-diabetic patients.

Claims

1. A system for treating kidney disease in diabetic and non-diabetic patients through an intravenous site administering a pulse of insulin to a patient comprising:

a) a means for determining a steady baseline respiratory quotient of the patient and obtaining a subsequent respiratory quotient every 30 minutes, the steady baseline respiratory quotient being two identical consecutive respiratory quotients less than 0.90 measured five minutes apart,

b) a liquid or food containing 60 to 100 grams of glucose, the liquid or food containing 60 to 100 grams of glucose being consumed by the patient, and

c) a means for administering intravenously the pulse of insulin at a regular interval of time until the subsequent respiratory quotient shows an improvement over the steady baseline respiratory quotient, the improvement being a respiratory quotient of 0.90 or greater, the subsequent respiratory quotient improvement over the steady baseline respiratory quotient being a measurement of sufficient insulin pulses to achieve a more normal metabolic function of a diseased kidney, the more normal metabolic function of a diseased kidney being a stabilization or decrease in 24-hour urinary protein excretion or a stabilization or increase in creatinine clearance.

2. The system of claim 1, wherein the intravenous site further comprises a needle or catheter located in the patient'"'"'s body, hand or forearm.

3. The system of claim 1, wherein the means for administering the pulse of insulin is an intravenous infusion device.

4. The system of claim 1, wherein the interval of time is about six minutes.

5. The system of claim 1, wherein the pulse of insulin is tailored to achieve a more normal metabolic function of the kidney.

6. The system of claim 1, wherein the intravenous site is converted to a heparin or a saline lock when the administration of insulin pulses has temporarily ceased between treatments.